PROSPECTION OF MEDICINAL CANNABIS IN THE BRAZILIAN MARKET: PRODUCTS, PRODUCTION METHODS, USE & INDUSTRIAL PROPERTY (IP)
The trajectory of medicinal Cannabis in Brazil began in academia in the 1970s, when Dr. Carlini published the first non-clinical study on rodents showing the bioprospecting of cannabidiol (CBD) as an anticonvulsant agent. Decades later, in 2014, medicinal Cannabis gained visibility with the case of girl Anny Fischer, who suffered from a rare and serious illness, allowing the family to gain authorization to import extracts containing high CBD and low delta-9-tetrahydrocannabinol. (THC) (> 0.2 mg). In the United States, the modern Cannabis industry is almost three decades old, beginning its rise in 1996 with the approval of medicinal use in California. Certainly, the prohibition of the Cannabis sativa L. plant favors difficult access to information about the therapeutic benefits linked to the legal Cannabis market. This review aims to introduce the basis of the production of legal cannabis products and present data from global and national markets. A bibliographical review was carried out based on NBR 10520 and 6023 (2002), on data released by the Canadian government, BDSA, ANVISA, Patient Associations and national and international patent banks. The results showed more than 250 imported products authorized by RDC335/2020, more than 60 products from associations and 18 products from national companies authorized by RDC 327/2019. In the area of Industrial Property, only 20 patent applications versus almost 70 thousand in the international market. We conclude that Brazil has a potentially promising market, at the beginning of its rise, and developing considerably, despite the prohibitions currently in force.
PROSPECTION OF MEDICINAL CANNABIS IN THE BRAZILIAN MARKET: PRODUCTS, PRODUCTION METHODS, USE & INDUSTRIAL PROPERTY (IP)
-
DOI: 10.22533/at.ed.813382322098
-
Palavras-chave: Cannabis sativa L. Medicinal cannabis. Prospection. Industrial Property (IP).
-
Keywords: Cannabis sativa L. Medicinal cannabis. Prospection. Industrial Property (IP).
-
Abstract:
The trajectory of medicinal Cannabis in Brazil began in academia in the 1970s, when Dr. Carlini published the first non-clinical study on rodents showing the bioprospecting of cannabidiol (CBD) as an anticonvulsant agent. Decades later, in 2014, medicinal Cannabis gained visibility with the case of girl Anny Fischer, who suffered from a rare and serious illness, allowing the family to gain authorization to import extracts containing high CBD and low delta-9-tetrahydrocannabinol. (THC) (> 0.2 mg). In the United States, the modern Cannabis industry is almost three decades old, beginning its rise in 1996 with the approval of medicinal use in California. Certainly, the prohibition of the Cannabis sativa L. plant favors difficult access to information about the therapeutic benefits linked to the legal Cannabis market. This review aims to introduce the basis of the production of legal cannabis products and present data from global and national markets. A bibliographical review was carried out based on NBR 10520 and 6023 (2002), on data released by the Canadian government, BDSA, ANVISA, Patient Associations and national and international patent banks. The results showed more than 250 imported products authorized by RDC335/2020, more than 60 products from associations and 18 products from national companies authorized by RDC 327/2019. In the area of Industrial Property, only 20 patent applications versus almost 70 thousand in the international market. We conclude that Brazil has a potentially promising market, at the beginning of its rise, and developing considerably, despite the prohibitions currently in force.
- Vinícius de Souza Major
- Lourival da Silva Fernandes
- MICHELINE FREIRE DONATO
